Yong-Yeon Cho | Biochemistry | Best Researcher Award

Prof. Yong-Yeon Cho | Biochemistry | Best Researcher Award

Professor at The Catholic University of Korea | South Korea

Prof.Yong-Yeon Cho is an accomplished biochemistry researcher recognized for his extensive contributions to molecular signaling, cancer biology, and drug development. His academic foundation includes rigorous training in biology, somatic cell genetics, and applied genetic engineering, forming the base for a career deeply rooted in experimental science and biochemical innovation. Over the years, he has held progressive research and academic positions, gaining broad expertise across molecular mechanisms of disease, pharmacological modulation, and therapeutic strategies. His research experience spans cellular signaling pathways, regulated cell death mechanisms, cancer chemoprevention, drug metabolism, nanoparticle-based delivery systems, immunological regulation, and translational pharmacology. He has made notable scientific contributions in areas such as ERK/RSK2 pathway targeting, UVB-induced autophagy, NLRP3 inflammasome regulation, organelle-targeted drug delivery, and the molecular foundations of metabolic and inflammatory diseases. His publication record reflects an exceptional level of productivity and global impact, with 186 peer-reviewed documents, 11,758 citations by 10,635 documents, and an impressive h-index of 49, demonstrating both the depth and influence of his work. His studies appear in leading journals across biochemistry, molecular biology, pharmacology, toxicology, and cancer research, highlighting his sustained commitment to advancing fundamental understanding while also bridging discoveries with potential clinical applications. His research interests continue to evolve across biochemical signaling networks, therapeutic biomaterials, immune regulation, toxicokinetics, and disease-associated molecular pathways, reflecting a multidisciplinary approach that integrates basic science with translational relevance. Throughout his career, he has collaborated on diverse scientific projects, contributed to international research initiatives, and helped develop emerging strategies for treating cancer, metabolic disorders, inflammatory diseases, and conditions driven by dysregulated cellular processes. Beyond producing high-impact research, he has also supported scientific progress through mentorship, scholarly leadership, and contributions to scientific discourse in multiple professional societies. His ongoing work continues to expand the boundaries of biochemistry and molecular medicine, positioning him as a leading figure whose research advances scientific knowledge while informing next-generation therapeutic innovations.

Profile: Scopus | Orcid | Google Scholar

Featured Publications:

Cho, Y.-Y.(2025). Loss of TC-PTP in keratinocytes leads to increased UVB-induced autophagy. Cell Death Discovery.

Cho, Y.-Y.(2025). Metabolite phenotyping of kobusin and identification of glutathione conjugates with kobusin catechol metabolite. Biomedicine & Pharmacotherapy.

Cho, Y.-Y.(2025). RSK2 and its binding partners: An emerging signaling node in cancers. [Journal name unavailable – Review article].

Cho, Y.-Y.(2025). Extracts from Allium pseudojaponicum Makino target STAT3 signaling pathway to overcome cisplatin resistance in lung cancer. Marine Drugs.

Cho, Y.-Y.(2024). SPOP-mediated RIPK3 destabilization desensitizes LPS/sMAC/zVAD-induced necroptotic cell death. Cellular and Molecular Life Sciences.

Cho, Y.-Y., Kim, M., Lee, S., et al. (2024). Safe and efficient treatment of drug-resistant colorectal cancer cells using kaempferol-loaded exosomes. Biotechnology and Bioprocess Engineering.

Cho, Y.-Y.(2024). RSK2-mediated cGAS phosphorylation induces cGAS chromatin-incorporation-mediated cell transformation and cancer cell colony growth. Cell Death Discovery.

Cho, Y.-Y.(2024). Ribosomal S6 kinase 2–forkhead box protein O4 signaling pathway plays an essential role in melanogenesis. Scientific Reports.

Cho, Y.-Y.(2024). Hepatocyte-specific RIG-I loss attenuates metabolic dysfunction-associated steatotic liver disease in mice via changes in mitochondrial respiration and metabolite profiles. Toxicological Research.

Cho, Y.-Y.(2024). Selective delivery of imaging probes and therapeutics to the endoplasmic reticulum or Golgi apparatus: Current strategies and beyond. Advanced Drug Delivery Reviews.

Dr.NABIL HASASNA | Hematomolecular pathologist | Future Science Leader Award

Dr.NABIL HASASNA | Hematomolecular pathologist | Future Science Leader Award

FELLOW at King Hussein Cancer Center, Jordan.

Dr. Nabil M. S. Hasasna is a dedicated and highly trained pathologist specializing in molecular and hemato-pathology. With over a decade of progressive experience across clinical pediatrics and diagnostic pathology, he is currently serving as a Fellow in Molecular Pathology at the esteemed King Hussein Cancer Center in Amman, Jordan. Known for his cross-disciplinary approach, Dr. Hasasna blends advanced diagnostic acumen with compassionate patient care, making him a valuable asset in the modern healthcare landscape.

Profile:

🎓 Educational Background:

Dr. Hasasna holds a Bachelor of Medicine and Bachelor of Surgery (MBBS) from Dow University of Health Sciences, Karachi, where he graduated with honors. He has earned prestigious certifications including the Diplomateship of the Royal College of Pathologists (UK) and the Arab Board in Anatomic Pathology. He also completed foundational stages in both the Arab and Palestinian Boards of Pediatrics, showcasing his diverse medical training.

Professional Experience:

Dr. Hasasna’s medical journey spans multiple disciplines. He served as a Pediatric Resident in various hospitals under the Palestine Ministry of Health, gaining hands-on experience in NICU, pediatric emergency, and hemato-oncology. Later, he advanced his expertise in pathology through a rigorous residency and fellowships at King Hussein Cancer Center, where he now contributes to cutting-edge diagnostic services in molecular and hemato-pathology.

Research Intrest:

Dr. Hasasna’s primary strengths lie in clinical diagnostics and laboratory medicine, he is currently focused on molecular-level cancer diagnostics, an area rapidly evolving with personalized medicine. His fellowships in Molecular-Pathology and Hemato-Pathology offer a platform for future research initiatives, particularly in genetic profiling and targeted therapies.

Honors and Recognitions:

Dr. Nabil M. S. Hasasna has earned notable recognition for his dedication to pathology and clinical excellence. He was awarded the Diplomateship of the Royal College of Pathologists (UK) in 2021, a prestigious certification that marks international distinction in diagnostic pathology. In the same year, he completed the Arab Board in Anatomic Pathology, a rigorous credential reflecting regional expertise in tissue-based diagnostics. His continuous academic advancement, including board qualifications in both surgical pathology and pediatrics, highlights his commitment to interdisciplinary excellence. Dr. Hasasna has contributed to impactful research, with publications cited internationally, and his work has gained visibility in respected journals such as the Journal of International Medical Research and Cancers. His professional affiliations with institutions like the King Hussein Cancer Center, known for high-level cancer diagnostics and research, further validate his reputation as a rising figure in molecular and hemato-pathology. These honors collectively reflect his growing influence in the medical and research community.

Publications:

🔹 APA Format:

Hasasna, N. M. S., [Other authors]. (2025). The role of [18F]FDG PET and clinicopathologic factors in detecting and predicting bone marrow involvement in non-Hodgkin lymphoma. Cancers.

🔹 MLA Format:

Hasasna, Nabil M. S., et al. “The Role of [18F]FDG PET and Clinicopathologic Factors in Detecting and Predicting Bone Marrow Involvement in Non-Hodgkin Lymphoma.” Cancers, 2025.

🔹 Chicago Style:

Hasasna, Nabil M. S., et al. 2025. “The Role of [18F]FDG PET and Clinicopathologic Factors in Detecting and Predicting Bone Marrow Involvement in Non-Hodgkin Lymphoma.” Cancers.

🔹 Vancouver Style:

Hasasna NMS, [Other authors]. The role of [18F]FDG PET and clinicopathologic factors in detecting and predicting bone marrow involvement in non-Hodgkin lymphoma. Cancers. 2025.